Biocryst Pharma: (NASD: BCRX)

$1.71

-0.08 (-4.47%)

Volume 477,614

Jun 19 03:59 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		1.70 - 1.80
	
		52wk Low - High
		1.08 - 4.95
	
		Previous Close
		1.79
	
		Avg. Volume
		607,613
	
		Industry
		MED-DRUGS
	
		Market Cap
		90.88 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		2.54
	
		P/E (F1)
		0.00
	
		Current Year Est.
		-0.47
	
		Quarterly Earnings ESP 
		-7.69%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		105 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/6/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.47
                        
                            Current Quarter Estimate
                            -0.13
                        
                            Most Accurate Estimate
                            -0.14
                        
                            Earnings ESP 
                            -7.69%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            -0.73
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.   
Full BCRX Company Report

 Snapshot on BCRX

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
BCRX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.13	-0.13	-0.47	-0.52
Number of Estimates	2	2	2	1
Low Estimate	-0.14	-0.14	-0.48	-0.52
High Estimate	-0.12	-0.11	-0.45	NA
Year Ago EPS	-0.25	-0.19	-0.77	-0.47
EPS Growth	48.00%	34.21%	39.61%	-11.83%

More BCRX Estimates

Average Earnings Estimates for BCRX

EPS Growth for BCRX

Industry Analysis

Name	Symbol	Previous Close
BIOCRYST PHARMA	BCRX	1.71
JAZZ PHARMACEUT	JAZZ	68.28
SALIX PHARM-LTD	SLXP	66.42
SANTARUS INC	SNTS	21.59
USANA HLTH SCI	USNA	72.92
ARADIGM CORP	ARDM	0.18
CELL THERAPEUT	CTIC	1.24
DURECT CORP	DRRX	0.83
ELAN CP PLC ADR	ELN	14.15
FLAMEL TECH	FLML	6.14

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Spectrum Pharma Reports 1Q Loss

May 14, 2013

Spectrum Acquires Apaziquone Rights

Feb 04, 2013

Synergy Starts SP-333 Phase I Study

Jan 29, 2013

Zacks Rank #1 Additions for Friday

Jan 25, 2013

EU Nod for Novo Nordisk Drugs

Jan 23, 2013

Positive CHMP Opinions for Novartis

Jan 23, 2013

Questcor Acquires BioVectra

Jan 22, 2013

Isis Pharma Updates on its Pipeline

Jan 11, 2013

More BCRX Zacks Commentary

Financials

EPS TTM	-0.73
Sales	26
Net Income	-38
Price/Earnings	NA
Price/Book	NA
Price/Cash Flow	NA
Price/Sales	5.16

More BCRX Financials

News

BioCryst Pharmaceuticals Q1 net loss decreases - Datamonitor

May 20, 2013

BioCryst Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 8, 2013

BioCryst Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 7, 2013

BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results - Businesswire

May 7, 2013

5 Stocks Under $10 Set to Surge - TheStreet.com

May 2, 2013

Before the Bell Scans of PDLI, BCRX, ARRY, and RPRX - Accesswire-Tnw

May 2, 2013

5 Health Care Stocks Under $10 to Watch - TheStreet.com

Apr 30, 2013

BioCryst Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon

Apr 24, 2013

See All News Stories on BCRX

Broker Recommendations

Current ABR	3.00
ABR (Last Week)	3.00
# of recs in ABR	3
Average Target Price	2.00
Industry Rank by ABR	105 out of 265
Rank in Industry	18 out of 95

More BCRX Broker Recommendations

Day Low - High	1.70 - 1.80
52wk Low - High	1.08 - 4.95
Previous Close	1.79
Avg. Volume	607,613
Industry	MED-DRUGS
Market Cap	90.88 M
Div - Yield	0.00 - 0.00
Beta	2.54
P/E (F1)	0.00
Current Year Est.	-0.47
Quarterly Earnings ESP	-7.69%

P/E (F1)	NA
PEG Ratio	NA
Current Year Est.	-0.47
Current Quarter Estimate	-0.13
Most Accurate Estimate	-0.14
Earnings ESP	-7.69%
Next Earnings Report Date	08-08-2013
EPS Last Year	-0.73
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Biocryst Pharma: (NASD: BCRX)

$1.71

-0.08 (-4.47%)

Volume 477,614

Jun 19 03:59 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations